An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Queen Mary University Of London

Participant type

Patients

Age range

18-64 years

Gender

Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

9 Dec 2025 → ongoing

Decision date (initial)

2025-10-24

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK

External identifiers

EU CT number

2024-519913-76-00

ClinicalTrials.gov

NCT06954480

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Efficacy, Safety

To demonstrate superiority of Dato-DXd plus
durvalumab relative to Dato-DXd alone in patients
with PD-L1-negative tumours as measured by
progression-free survival (PFS).

Secondary objectives 4

1. To compare Dato-DXd plus durvalumab relative to Dato-DXd alone in patients with PD-L1-negative tumours as measured by overall survival (OS)
2. To compare Dato-DXd plus durvalumab relative to Dato-DXd alone in patients with PD-L1-negative tumours as measured by objective response rates (ORR), clinical benefit rate (CBR), duration of response (DoR) and duration of clinical benefit
3. To assess changes in quality of life (QoL) as assessed by patient reported outcomes (PROs) in patients treated with Dato-DXd plus durvalumab versus Dato-DXd
4. To evaluate the safety and tolerability of Dato-DXd plus durvalumab versus Dato-DXd

Conditions and MedDRA coding

PDL1-negative metastatic triple-negative breast cancer

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 11

1. Willing and able to provide written informed consent
2. Ability to comply with the protocol
3. Female and male ≥ 18 years of age
4. Patients with locally advanced unresectable or metastatic (stage IV) triple-negative breast cancer, defined as tumour cells being o Negative for ER with <10% of tumour cells positive for ER on IHC or IHC score (Allred) of ≤3 o Negative for PR with <10% of tumour cells positive for PR on IHC or IHC score (Allred) of ≤3 or PR unknown, and o Negative for HER2 with 0, 1+ or 2+ intensity on IHC and no evidence of amplification on ISH.
5. PD-L1 negative, defined as o 22C3 CPS<10
6. Patients must have: at least one lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computed tomography (CT) or magnetic resonance imaging (MRI) performed within 28 days prior to randomisation which is suitable for accurate repeated measurements, or o lytic or mixed (lytic + sclerotic) bone lesions in the absence of measurable disease as defined above; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible Patients that cannot be assessed by the CT or MRI scan should be excluded.
7. Representative formalin-fixed paraffin embedded (FFPE) breast tumour samples with an associated pathology report from the primary or recurrent cancer that are determined to be available and sufficient for central testing OR tumour accessible for biopsy.
8. ECOG performance status 0-1
9. Adequate haematologic and end-organ function within 28 days prior to the first study treatment defined by the following: o ANC ≥ 1500 cells/μL (1.5 x 109/L) (without granulocyte colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1) o WBC > 2500/μL (2.5 x 109/L) o Platelet count ≥ 100,000/μL (100 x 109/L) (transfusion not permitted within 28 days of study medication) o Haemoglobin ≥ 9.0 g/dL (90g/L) with no blood transfusions (packed red blood cells) o Serum albumin ≥ 3g/dL o AST (SGOT) or ALT (SGPT) and ALP ≤ 2.5 times the institutional upper limit of normal (ULN), bilirubin ≤ 1.5 x ULN (patients with liver metastases who have AST or ALT ≤ 5 x the institutional ULN may be enrolled), o aPTT ≤ 1.5 × the institutional ULN, INR <1.5 and absence of evidence of impaired hepatic synthesis function. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose o Serum Creatinine ≤ 1.5 x ULN. o Glomerular filtration rate ≥ 40mL/min as assessed by standard methodology at the investigating center (i.e., CockcroftGault, MDRD or CKD-EPI formulae, EDTA clearance or 24 h urine collection) o No evidence of haematuria: +++ on microscopy or dipstick
10. Patients of childbearing potential are eligible provided they have a negative serum or urine pregnancy test on Cycle 1, Day 1 (within 72 hours) of study treatment, preferably as close to the first dose as possible. Patients must agree to use adequate contraception, defined as those methods with a failure rate of < 1 % per year beginning 14 days before the first dose of study drug and for 7 months after the last dose of study drug. Also, participants must not donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of treatment. Preservation of ova should be considered prior to randomization or the first dose of study intervention. Fertile men with a female partner of childbearing potential must agree to use one barrier method of contraception, such as condom, during treatment on this trial and for up to 4 months after the last dose of treatment. Male participants must not donate sperm from the start of dosing for at least 4 months after the last dose of the treatment.
11. Body Weight > 30 kg

Exclusion criteria 28

1. Prior chemotherapy, immunotherapy (including durvalumab) or treatment with PARP inhibitors for advanced or metastatic breast cancer
2. Prior treatment with immune checkpoint inhibitors (eg atezolizumab, pembrolizumab) or DNA topoisomerase I or TROP2- or HER2-targeting ADCs and TROP2 targeted therapy in the (neo)adjuvant setting within 6 months from the end of treatment and randomisation into this study
3. Patients with prior allogeneic stem cell or solid organ transplantation
4. Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent), or had oral or IV steroids for 14 days prior to the first dose of study drug; the use of intranasal, inhaled corticosteroids topical steroids, or local steroid injections, physiologic replacement doses of glucocorticoids (i.e. for adrenal insufficiency) and mineralocorticoids (e.g. fludrocortisone) or steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) is allowed.
5. Administration of a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
6. Active or prior documented autoimmune or inflammatory disorders including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis,or glomerulonephritis. The following are exceptions to this criterion: o Patients with vitiligo or alopecia o Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy o Any chronic skin condition that does not require systemic therapy o Patients without active disease in the last 5 years may be included o Patients with celiac disease controlled by diet alone
7. History of idiopathic pulmonary fibrosis (including pneumonitis or interstitial lung disease), druginduced pneumonitis, radiation pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia) requiring steroids, or evidence of active pneumonitis on screening chest CT scan.
8. Active infection requiring systemic therapy.
9. History of HIV infection
10. Known active hepatitis infection (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
11. Known history of active tuberculosis clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
12. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator’s opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
13. Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol
14. Concurrent treatment with other experimental drugs or participation in another clinical trial with therapeutic intent within 28 days prior to randomisation
15. Pregnant and lactating female patients
16. Major surgical procedure within 4 weeks prior to randomisation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
17. Malignancies other than breast cancer within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent)
18. Severe infections within 28 days prior to randomisation in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia
19. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria o Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. o Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
20. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, situations that would limit compliance with study requirement, substantially increase risk of incurring AEs
21. History of leptomeningeal carcinomatosis
22. Has clinically significant corneal disease.
23. Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
24. History of active primary immunodeficiency
25. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
26. Patient with Brain metastases or neoplastic spinal cord compression. Patients whose brain metastases have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression. In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of ≤10mg/day of prednisone or its equivalent and anticonvulsants for at least 14 days prior to the start of treatment. Brain metastases will not be recorded as RECIST Target Lesions at baseline.
27. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).
28. Patients who have received prior anti–PD-1, anti PD-L1 or anti CTLA-4: o Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy o All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study o Must not have experienced a ≥Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of ≤Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic. o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. PFS is defined as the time from the date of randomisation to the date of first documented confirmed tumour progression (using RECIST 1.1) or death from any cause, whichever occurs first in all patients.

Secondary endpoints 7

1. OS is defined as the time from date of randomisation to the date of death due to any cause in all patients
2. ORR is defined as the proportion of the patients in the analysis population who have a complete response (CR) or partial response (PR) (using RECIST 1.1).
3. DoR is defined as the time from first documentation of CR or PR to confirmed disease progression using RECIST 1.1, or death on study from any cause, whichever occurs first, in patients with objective response.
4. CBR is defined as the percentage of patients who have achieved at least one CR or PR or met the SD criteria at least once after randomisation for a minimum interval of 24 weeks (using RECIST 1.1).
5. DoCB is calculated as time (in months) from randomisation to progression or death from any cause in patients with a clinical benefit.
6. Changes in quality of life measured by the time to deterioration (TTD) in Items 29 (overall health) and 30 (overall QoL) of the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and the percentages of patients with a decrease or increase of ≥ 10 points on the global health status/HRQoL scale of the EORTC QLQ-C30 and on subsets, respectively.
7. Incidence, nature and severity of adverse events with severity determined according to CTCAE v5.0.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Queen Mary University Of London

Sponsor organisation

Queen Mary University Of London

Address

327 Mile End Road

City

London

Postcode

E1 4NS

Country

United Kingdom

Scientific contact point

Organisation

Queen Mary University Of London

Contact name

Dr Mays Jawad

Public contact point

Organisation

Queen Mary University Of London

Contact name

Dr Mays Jawad

Third parties 4

Locations

2 EU/EEA countries · 19 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 13 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

4 submissions — initial application plus substantial / non-substantial modifications